Back to Journals » Vascular Health and Risk Management » Volume 3 » Issue 1
Vascular Health and Risk Management
ISSN: 1178-2048
- View all (1529)
- Volume 20, 2024 (33)
- Volume 19, 2023 (86)
- Volume 18, 2022 (87)
- Volume 17, 2021 (80)
- Volume 16, 2020 (60)
- Volume 15, 2019 (54)
- Volume 14, 2018 (42)
- Volume 13, 2017 (54)
- Volume 12, 2016 (52)
- Volume 11, 2015 (66)
- Volume 10, 2014 (74)
- Volume 9, 2013 (73)
- Volume 8, 2012 (74)
- Volume 7, 2011 (92)
- Volume 6, 2010 (113)
- Volume 5, 2009 (112)
- Volume 4, 2008 (164)
- Volume 3, 2007 (113)
- Volume 2, 2006 (57)
- Volume 1, 2005 (43)
Archive: Volume 3, 2007
Blood pressure normalization in a large population of hypertensive patients treated with perindopril/indapamide combination: results of the OPTIMAX trial
Jean-Jacques Mourad, Viet Nguyen, Marilucy Lopez-Sublet, Bernard Waeber
Vascular Health and Risk Management 2007, 3:173-180
Published Date: 15 March 2007
Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials
Ramzi EL Féghali, Sophie Nisse-Durgeat, Roland Asmar
Vascular Health and Risk Management 2007, 3:165-171
Published Date: 15 March 2007
Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
Allen J Taylor, Daming Zhu, Lance E Sullenberger, Hyun J Lee, Jeannie K Lee, Karen A Grace
Vascular Health and Risk Management 2007, 3:159-164
Published Date: 15 March 2007
A review of sitaxsentan sodium in patients with pulmonary arterial hypertension
Aaron B Waxman
Vascular Health and Risk Management 2007, 3:151-157
Published Date: 15 March 2007
Overweight, physical activity and high blood pressure in children: a review of the literature
Brian Torrance, K Ashlee McGuire, Richard Lewanczuk, Jonathan McGavock
Vascular Health and Risk Management 2007, 3:139-149
Published Date: 15 March 2007
Role of the vasodilator peptide angiotensin-(1–7) in cardiovascular drug therapy
Christoph Schindler, Peter Bramlage, Wilhelm Kirch, Carlos M Ferrario
Vascular Health and Risk Management 2007, 3:125-137
Published Date: 15 March 2007
Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis
Peter J Little, Mandy L. Ballinger, Narin Osman
Vascular Health and Risk Management 2007, 3:117-124
Published Date: 15 March 2007
Management of atrial fibrillation
Puneet Kakar, Christopher J Boos, Gregory YH Lip
Vascular Health and Risk Management 2007, 3:109-116
Published Date: 15 March 2007
Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels
Jutta Dierkes, Claus Luley, Sabine Westphal
Vascular Health and Risk Management 2007, 3:99-108
Published Date: 15 March 2007
A review of picotamide in the reduction of cardiovascular events in diabetic patients
Andrea Celestini, Francesco Violi
Vascular Health and Risk Management 2007, 3:93-98
Published Date: 15 March 2007
Inhaled human insulin (Exubera®): clinical profile and patient considerations
Anthony H Barnett, Sri Bellary
Vascular Health and Risk Management 2007, 3:83-91
Published Date: 15 March 2007
Trandolapril/verapamil combination in hypertensive diabetic patients
José A García Donaire, Luis M Ruilope
Vascular Health and Risk Management 2007, 3:77-82
Published Date: 15 March 2007
Foot ulcers in the diabetic patient, prevention and treatment
Stephanie C Wu, Vickie R Driver, James S Wrobel, David G Armstrong
Vascular Health and Risk Management 2007, 3:65-76
Published Date: 15 March 2007
Cardiometabolic aspects of polycystic ovarian syndrome
Li Wei Cho, Harpal S Randeva, Stephen L Atkin
Vascular Health and Risk Management 2007, 3:55-63
Published Date: 15 March 2007
What is the future of peer review? Why is there fraud in science? Is plagiarism out of control? Why do scientists do bad things? Is it all a case of: “All that is necessary for the triumph of evil is that good men do nothing?”
Chris R Triggle, David J Triggle
Vascular Health and Risk Management 2007, 3:39-53
Published Date: 15 March 2007
Carvedilol in the treatment of chronic heart failure: Lessons from The Carvedilol Or Metoprolol European Trial
Britt Kveiborg, Atheline Major-Petersen, Buris Christiansen, Christian Torp-Pedersen
Vascular Health and Risk Management 2007, 3:31-37
Published Date: 15 March 2007
Moexipril and left ventricular hypertrophy
George S Chrysant, PK Nguyen
Vascular Health and Risk Management 2007, 3:23-30
Published Date: 15 March 2007
A review of pulmonary arterial hypertension: role of ambrisentan
Robyn J Barst
Vascular Health and Risk Management 2007, 3:11-22
Published Date: 15 March 2007
Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from The ONTARGET Trial Programme
Luis Miguel Ruilope, Josep Redón, Roland Schmieder
Vascular Health and Risk Management 2007, 3:1-9
Published Date: 15 March 2007